Research programme: anti-archaea therapeutics - Synthetic Biomics

Drug Profile

Research programme: anti-archaea therapeutics - Synthetic Biomics

Alternative Names: Anti-infectives - Synthetic Biomics

Latest Information Update: 07 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cedars-Sinai Health System
  • Developer Cedars-Sinai Health System; Synthetic Biomics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 07 Oct 2015 No development reported for Obesity in USA (PO)
  • 07 Oct 2015 No development reported for Type-2 diabetes mellitus in USA (PO)
  • 17 Dec 2013 Synthetic Biomics enters into worldwide license and option agreement with Cedars-Sinai to develop new anti-archaea therapies for chronic diseases (e.g. irritable bowel syndrome, obesity and type 2 diabetes)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top